Home > News > NCI Seminar Highlights Progress in Anticancer Nanomedicines
October 5th, 2005
NCI Seminar Highlights Progress in Anticancer Nanomedicines
Abstract:
Though many observers believe that the application of nanotechnology in medicine is a recent phenomenon, "progress in the development of nano-sized hybrid therapeutics and nanosized drug delivery systems over the past decade has been remarkable," said Ruth Duncan, Ph.D., director of the center for polymer therapeutics at Cardiff University in Wales. Speaking at the most recent NCI-sponsored Nanotechnology Seminar Series, Duncan noted that routine clinical use and clinical development of nano-sized drug delivery vectors including liposomes, antibody conjugates, nanoparticles and polymer therapeutics as anticancer treatments is growing rapidly.
Source:
nano.cancer.gov
Related News Press |
Possible Futures
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Materials/Metamaterials/Magnetoresistance
Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024
Focused ion beam technology: A single tool for a wide range of applications January 12th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||